Drug Trial Radar · NCT05473624
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
153
Planned (sponsor's estimate)
Start
Aug 23, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
HRS-1167Drug
Participants will receive HRS-1167.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT) of HRS-1167Time frame: up to 24 days
- Maximum tolerated dose (MTD) of HRS-1167Time frame: up to 24 months
- Recommended Phase II Dose (RP2D) of HRS-1167Time frame: up to 24 months
- AEs+SAEsTime frame: up to 24 months
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Guangxi Medical University Affiliated Tumor Hosipital
Nanning, Guangxi, China · Recruiting
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shangdong, China · Recruiting
Shandong Cancer Hospital
Jinan, Shangdong, China · Recruiting
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhengjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.